tirzepatide clinicaltrials.gov Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study Highlighting 3 ongoing clinical trials

Constantly monitor blood sugar levels to avoid hypoglycemia

The price is great and it works

Both contain the same active ingredient but are approved for different clinical indications and are manufactured by Eli Lilly and Company

Patients should contact their GP or diabetes specialist nurse if they experience: Polyuria with polydipsia (excessive thirst) this combination may indicate inadequate glycaemic control or, rarely, diabetic ketoacidosis (DKA), which requires urgent medical attention Dysuria (painful urination) suggesting possible urinary tract infection, which people with diabetes are at increased risk of developing Nocturia (frequent nighttime urination) when new or worsening, this may reflect various causes including poorly controlled diabetes that require clinical assessment Urinary urgency or incontinence potentially indicating bladder dysfunction or infection requiring investigation Dark, concentrated urine with reduced output this may signal dehydration, particularly if accompanied by persistent vomiting or diarrhoea from gastrointestinal side effects According to NICE guideline NG28 on type 2 diabetes management, any significant change in urinary symptoms warrants assessment of glycaemic control through HbA1c or blood glucose monitoring, urinalysis to exclude infection or glycosuria, and evaluation of fluid balance

Heres how to stay within the rules and continue leveraging the benefits of compounding: 1

Since tirzepatide inherently slows gastric emptying as part of its mechanism of action, administering it to patients with pre-existing gastroparesis could potentially worsen their condition and lead to severe gastrointestinal complications